Clinical Trial Detail

NCT ID NCT01970865
Title A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Pfizer
Indications

lung non-small cell carcinoma

Therapies

Lorlatinib

Crizotinib

Age Groups: adult

Additional content available in CKB BOOST